|1.||Wright, J T: 9 articles (04/2007 - 01/2000)|
|2.||Gibson, Carolyn W: 8 articles (09/2014 - 01/2005)|
|3.||Li, Yong: 6 articles (09/2014 - 05/2006)|
|4.||Snead, Malcolm L: 6 articles (12/2011 - 05/2002)|
|5.||Kulkarni, Ashok B: 5 articles (12/2011 - 01/2005)|
|6.||Gibson, C W: 5 articles (04/2007 - 01/2001)|
|7.||Moradian-Oldak, Janet: 4 articles (08/2015 - 03/2002)|
|8.||Wright, J Timothy: 4 articles (09/2014 - 01/2005)|
|9.||Hart, T C: 4 articles (01/2003 - 07/2000)|
|10.||Hart, P S: 4 articles (01/2003 - 07/2000)|
07/01/2012 - "New insights into therapy by mathematical analysis: recalcitrant granulated improved more than sclerotic venous leg ulcers with amelogenin treatment."
12/01/2012 - "To determine the effect of topically applied amelogenin extracellular matrix protein(AEMP) in patients with non-healing venous leg ulcers combined with atrophie blanche. "
12/01/2012 - "Effect of amelogenin ECM protein on the healing of chronic leg ulcers with atrophie blanche."
07/01/2012 - "To prove the hypotheses for a divergent therapeutic outcome, we treated granulated vs. sclerotic chronic venous leg ulcers with amelogenin (Xelma®) 1×/week for 5-8 weeks. "
05/01/2009 - "To assess the cost-effectiveness of using amelogenin plus compression bandaging versus compression bandaging alone in treating non-healing venous leg ulcers (VLUs) of over six months duration, from the perspective of the national health service in England. "
05/01/2007 - "The number of improved ulcers was significantly greater (p = 0.01) in the amelogenin group than in the control group. "
01/01/2008 - "Significantly more patients continued to show a reduction in ulcer size from baseline in the amelogenin-treated group versus the control group (p=0.02), and there was a statistically significant (p=0.01) larger reduction in the amelogenin-treated group. "
05/01/2007 - "The combination of amelogenin with high compression promotes the healing process in hard-to-heal ulcers. "
05/01/2007 - "Compensating for baseline characteristics by multiple regression resulted in a statistically significant (p = 0.03) larger reduction in change in ulcer size in the amelogenin group. "
05/01/2007 - "The amelogenin group had a greater percentage reduction in ulcer size (mean - 33.1%) compared with the control group (mean - 11.07%) from baseline to the last visit (p = 0.06). "
01/01/2008 - "Pain continued to be significantly reduced in the amelogenin-treated group compared with the control group (p=0.001). "
05/01/2007 - "Application of amelogenin as an adjunct to compression results in a significant reduction in ulcer size, improvement in the state of ulcers, reduced pain and a larger proportion of ulcers with low levels of exudate. "
05/01/2007 - "Statistically significant differences in favour of the amelogenin group were also found for reduction in ulcer-related pain (p = 0.01), reduction in pain at dressing changes (p = 0.02) and the proportion of patients with 'none' or 'low' levels of exudate (p = 0.01). "
01/01/2008 - "A randomized controlled trial (RCT) involving patients with hard-to-heal venous leg ulcers (VLUs) (ie, ulcers with a surface > or = area 10 cm2 and duration of > or = 6 months) showed that the application of amelogenin (Xelma, Molnlycke Health Care, Gothenburg, Sweden) as an adjunct treatment to compression results in significant reduction in ulcer size, improvement in the state of ulcers, reduced pain, and a larger proportion of ulcers with low levels of exudate, compared with treatment with compression alone. "
|4.||Wounds and Injuries (Trauma)
06/01/2009 - "Also, the response of CRL-7815 fibroblasts to the extracellular matrix protein amelogenin that is beneficial in the treatment of stalled chronic wounds was studied. "
03/26/2009 - "This article examines the findings of studies relating to amelogenin in the treatment of hard-to-heal wounds."
03/26/2009 - "The use of amelogenin (Xelma, Mölnlycke Health Care) for the treatment of a variety of chronic wounds has been assessed in both case studies and larger clinical trials with encouraging findings. "
01/01/2008 - "Pre-clinical and clinical studies indicate that cutaneous wounds benefit from treatment with amelogenins. "
07/01/2012 - "A new therapeutic option for those wounds might be amelogenin, which supplies a temporary matrix to the fibroblasts and keratinocytes. "
09/01/2014 - "The purposes of this study were to: (1) investigate adhesion through shear bond strength (SBS) testing of a resin composite bonded with a self-etching bonding system (SEB) to amelogenesis imperfecta (AI)-affected deproteinized mouse enamel or dentin; and (2) compare wild-type (WT), amelogenin null (AmelxKO), and matrix metalloproteinase-20 null (Mmp20KO) enamel and dentin phenotypes using micro-CT and nanoindentation. "
01/01/2014 - "The aim of this study was to report the clinical findings and the screening of mutations of amelogenin gene of a 7-year-old boy with amelogenesis imperfecta (AI). "
03/01/2002 - "Amelogenins, the major protein component of the mineralizing enamel extracellular matrix, are critical for normal enamel formation as documented in the linkage studies of a group of inherited disorders, with defective enamel formation, called Amelogenesis imperfecta. "
11/01/1998 - "In this study, we have determined the nucleotide sequences of regions of the intron 1 and intron 2 of the X and Y human amelogenin genes (AMGX, AMGY) for the first time, and established a polymerase chain reaction (PCR) protocol to amplify six exons of AMGX and AMGY for the diagnosis of amelogenesis imperfecta, because previous studies have shown that some of the AI patients have such mutations. "
03/01/1995 - "In this study we describe a 9-bp deletion in exon 2 of the amelogenin gene (AMGX) causing X-linked hypoplastic amelogenesis imperfecta, a disease characterized by defective enamel. "
|2.||Proteins (Proteins, Gene)
|3.||Matrix Metalloproteinase 20
|6.||Messenger RNA (mRNA)
|7.||Calcifying Epithelial Odontogenic Tumor
|9.||DNA (Deoxyribonucleic Acid)
|5.||Dental Cavity Preparation